Roche says entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy......»»

Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States......»»

Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment......»»

Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics clearing the way for the Swiss drugmaker's push into treating rare diseases including hemophilia A......»»

For the 10th time this year, Roche has extended its $114.50 per share tender offer to Spark Therapeutics stockholders. In February, Roche of Basel, Switzerland, entered into an agreement to buy Philadelphia gene therapy pioneer Spark Therapeutics for $4.....»»

Astellas Pharma Inc.’s $3 billion acquisition of Audentes Therapeutics is a strong indicator that the pharmaceutical industry’s march into gene therapy development isn’t going to slow down in 2020......»»

One of the leading Cambridge biotechs hoping to treat diseases by silencing the underlying genetic cause has signed a billion-dollar deal to develop a hepatitis B treatment.  Drug giant Roche will pay $200 million upfront and up to $1.47 billion i.....»»

The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday......»»

The slow-moving regulatory review process is once again being blamed for the latest delay in Roche’s proposed $4.3 billion acquisition of Philadelphia gene therapy pioneer Spark Therapeutics Inc. Roche said on Monday it is extending the offering per.....»»

Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue......»»

Roche has extended, yet again, its tender offer to Spark Therapeutics in connection with the proposed $4.3 billion purchase of the Philadelphia gene therapy pioneer. For those keeping track, this is the fifth time the companies announced a new deadl.....»»

Roche and Spark Therapeutics announced another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews in the United States and Britain continue......»»

Swiss drugmaker Roche has agreed to extend the takeover deadline in its $4.3 billion bid for U.S. gene therapy specialist Spark Therapeutics , adding it remains "fully committed" to the transaction and expects it to close this year......»»

Swiss drug giant Roche Holdings AG Basel ADR (OTC: RHHBY) has announced another delay in its proposed takeover of the gene therapy biotech Spark Therapeutics Inc (NASDAQ: ONCE). read more.....»»

The finish line for their proposed $4.8 billion deal is proving to be quite elusive for Roche and Spark Therapeutics. The companies announced Monday they have have each received a request for additional information and documentary material from the F.....»»

Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»